Skip to main content
Signal8

Karyopharm Therapeutics Inc. (KPTIQ)

Sector: Pharmaceutical Preparations

Industry: Medical - Pharmaceuticals

Karyopharm Therapeutics, Inc. logo

Karyopharm Therapeutics, Inc.

OTC:KPTIQOTC (suspended from Nasdaq on Nov 11, 2026)Healthcare
+39.16%$0.0398
Mkt Cap$903K
EV-
Float21.62M
O/S22.68M
VOL2.31M sh
$ Vol$81K
RVOL0.71×
Inst Own76.4%
Net Cash/Sh-
Dilution
Karyopharm Therapeutics, Inc. logoOTC:KPTIQ$0.0398+39.16%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20260.02900.04170.02860.03982,313,371
Nov 16, 20260.02200.02900.02200.02861,373,924
Nov 13, 20260.02750.02900.02100.02541,575,002
Nov 12, 20260.01020.02750.01020.02552,847,972
Nov 11, 20260.00800.02000.00800.01758,359,730
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
76.4%
Institutional
(92)
5.4%
Insiderⓘ
(14)
32.1%
5%+ Owners
(5)
-
Unattributed (incl. retail)ⓘ
Institutional76.4%
Insider5.4%
5%+ Beneficial32.1%
Sources: 13F, Form 4, 13D/13GO/S: 22.7M · as of 6 Aug 2026 · SEC cover page
Insiders & Institutional Holders
About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors.

In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Key Metrics
Market Cap$902,722
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership76.39%

based on 22.68M shares outstanding

SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeOTC
CountryUSUS
IPO Date-
Shares Outstanding22.68M
Authorized Shares
Float21.62M
52-Week Range
Volume
Average Daily Volume3.28M
2.31M today vs 3.28M avg(-29%)

30d Avg

3.28M

60d Avg

3.28M

90d Avg

3.28M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Karyopharm Therapeutics Inc. (OTC: KPTIQ) traded at $0.0398 on Nov 17, 2026, up 39.16% from the previous close of $0.0286. The company is in the Healthcare sector (Medical - Pharmaceuticals).